When Approvable Is Good News: Forest Gets January Launch for Bystolic

Is there a way out of the woods for new drug sponsors seeking FDA approval for products with broad primary care indications? Forest may have found a path with nebivolol, but the formula is not one that will excite many other drug sponsors.

Cole Werble

In the current new drug approval climate maybe even an "approvable" letter from the Food & Drug Administration is a...

More from Archive

More from Pink Sheet